<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04760548</url>
  </required_header>
  <id_info>
    <org_study_id>SA-AI</org_study_id>
    <nct_id>NCT04760548</nct_id>
  </id_info>
  <brief_title>Segmentation of Structural Abnormalities in Chronic Lung Diseases</brief_title>
  <official_title>Segmentation of Structural Abnormalities in Chronic Lung Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital Haut Lévêque</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre National de la Recherche Scientifique, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hôpital Haut-Lévêque</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lung structural abnormalities are complex, time-consuming, and may lack reproducibility to&#xD;
      evaluate visually on CT scans. The study's aim is to perform automated recognition of&#xD;
      structural abnormalities in CT scans of patients with chronic lung diseases by using&#xD;
      dedicated software.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Three chronic lung diseases will constitute the target of the study, by using retrospective&#xD;
      data from each lung disease:&#xD;
&#xD;
        -  Cystic fibrosis&#xD;
&#xD;
        -  Asthma and COPD&#xD;
&#xD;
        -  Interstitial lung diseases&#xD;
&#xD;
      Dedicated algorithms will be developped for each disease condition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2008</start_date>
  <completion_date type="Anticipated">February 17, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 17, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Validity of automated measurement</measure>
    <time_frame>From date of inclusion until the date of final quantification, assessed up to 12 months</time_frame>
    <description>Correlations and comparisons with other biomarker of the disease severity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation with pulmonary function test</measure>
    <time_frame>From date of inclusion until the date of final quantification, assessed up to 12 months</time_frame>
    <description>Correlation of quantitative measurement with pulmonary function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal variation over time</measure>
    <time_frame>From date of inclusion until the date of final quantification, assessed up to 12 months</time_frame>
    <description>Comparison of quantitative measurement at two time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reproducibility</measure>
    <time_frame>From date of inclusion until the date of final quantification, assessed up to 12 months</time_frame>
    <description>Evaluation of measurements when performed twice</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Asthma</condition>
  <condition>COPD</condition>
  <condition>Interstitial Lung Disease</condition>
  <arm_group>
    <arm_group_label>Train dataset</arm_group_label>
    <description>This group is dedicated to developing an automated algorithm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test dataset</arm_group_label>
    <description>This group is dedicated to testing the performance of an automated algorithm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clinical Validation</arm_group_label>
    <description>This group is dedicated to assessing the clinical validity of the measurement in an independent validation cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational study</intervention_name>
    <arm_group_label>Clinical Validation</arm_group_label>
    <arm_group_label>Test dataset</arm_group_label>
    <arm_group_label>Train dataset</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic lung disease and a Clinical examination, pulmonary function test, and&#xD;
        CT acquired during an annual routine follow-up&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with chronic lung disease and clinical examination, pulmonary function test,&#xD;
             and CT acquired during a routine follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  In the Clinical Validation group, patients with exacerbation or part of the other&#xD;
             groups&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francois Laurent, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>Hopital Haut Leveque</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Haut Leveque</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 15, 2021</study_first_submitted>
  <study_first_submitted_qc>February 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hôpital Haut-Lévêque</investigator_affiliation>
    <investigator_full_name>Hôpital Haut Lévêque</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Automated software measurements</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

